Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of post-transplant cyclophosphamide as sole graft-versus-host disease prophylaxis (OCTET-CY)
2010-022058-18Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by University of Cologne. Started Jan 2011; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2010-022058-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022058-18.